Diginex Integrates Risk-to-Remedy to Strengthen Supply Chain Due Diligence Amid Regulatory Crackdown

Event summary

  • Diginex has integrated Risk-to-Remedy, an end-to-end supply chain due diligence solution, combining LUMEN for risk assessment, APPRISE for worker engagement, and The Remedy Project’s expertise in grievance mechanisms.
  • The solution aims to close the gap between corporate declarations and demonstrable evidence, addressing regulatory requirements for labor exploitation remediation.
  • The human rights and supply chain due diligence market is valued at $3.8 billion in 2025 and projected to reach $9.6 billion by 2034.
  • Upcoming enhancements will include more efficient assessment management, evidence collection, non-compliance monitoring, and regulator-ready reporting.
  • Diginex’s diginexESG platform supports multiple global frameworks, including GRI, SASB, and TCFD.

The big picture

Diginex’s move comes as regulatory frameworks like the UK Modern Slavery Act and the EU Forced Labour Regulation tighten, requiring organizations to demonstrate defensible evidence of labor exploitation remediation. The $3.8 billion human rights and supply chain due diligence market is expanding rapidly, driven by increased investor scrutiny and the need for responsible sourcing. Diginex’s integration of Risk-to-Remedy positions it to support businesses in building resilient, transparent supply chains amid growing regulatory pressure.

What we're watching

Regulatory Compliance
How the integration of Risk-to-Remedy will position Diginex to meet evolving global supply chain due diligence regulations.
Market Expansion
Whether Diginex can capitalize on the projected growth of the $9.6 billion supply chain due diligence market by 2034.
Execution Risk
The pace at which Diginex can enhance its supply chain offering to manage assessments, collect evidence, and maintain regulator-ready records.